Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMO 1

Next Previous
Drug Profile

OMO 1

Alternative Names: DO-1; JNJ-38877618; OMO-1

Latest Information Update: 30 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen-Cilag; Octimet Oncology
  • Class Antineoplastics; Pyridazines; Pyridines; Quinolines; Small molecules; Triazoles
  • Mechanism of Action Organic cation transporter 2 inhibitors; Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Cancer

Most Recent Events

  • 30 Nov 2022 OMO 2 licensed to DeuterOncology worldwide excluding greater China (DeuterOncology pipeline, March 2023)
  • 16 Sep 2020 OMO 1 licensed to Allist Pharmaceuticals in HongKong, Macau, China and Taiwan
  • 16 Sep 2020 Allist pharmaceuticals plans a clinical trial (Combination therapy) for Non-small cell lung cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top